Microglia Purinoceptor P2Y6: An Emerging Therapeutic Target in CNS Diseases

Cells. 2020 Jul 1;9(7):1595. doi: 10.3390/cells9071595.

Abstract

The purinergic receptor P2Y6 is expressed in immune cells, including the microglia that are implicated in neurological disorders. Its ligand, UDP, is a signaling molecule that can serve as an "find-me" signal when released in significant quantities by damaged/dying cells. The binding of UDP by P2Y6R leads to the activation of different biochemical pathways, depending on the disease context and the pathological environment. Generally, P2Y6R stimulates phagocytosis. However, whether or not phagocytosis coincides with cell activation or the secretion of pro-inflammatory cytokines needs further investigation. The current review aims to discuss the various functions of P2Y6R in some CNS disorders. We present evidence that P2Y6R may have a detrimental or beneficial role in the nervous system, in the context of neurological pathologies, such as ischemic stroke, Alzheimer's disease, Parkinson's disease, radiation-induced brain injury, and neuropathic pain.

Keywords: P2Y6R; microglia; neuroinflammation; phagocytosis; pro-inflammatory cytokines.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Alzheimer Disease / metabolism
  • Brain Injuries / metabolism
  • Central Nervous System Diseases / metabolism*
  • Cytokines / metabolism
  • Humans
  • Inflammation / immunology
  • Inflammation / metabolism
  • Ischemic Stroke / metabolism
  • Microglia / metabolism*
  • Microglia / pathology
  • Neuralgia / metabolism
  • Parkinson Disease / metabolism
  • Phagocytosis / genetics
  • Phagocytosis / immunology
  • Receptors, Purinergic P2 / metabolism*

Substances

  • Cytokines
  • Receptors, Purinergic P2
  • purinoceptor P2Y6

Grants and funding